©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 7, 2013; 19(21): 3199-3206
Published online Jun 7, 2013. doi: 10.3748/wjg.v19.i21.3199
Published online Jun 7, 2013. doi: 10.3748/wjg.v19.i21.3199
Table 4 Major adverse events during sofosbuvir and ABT-450 regimens
| Adverse events | Sofosbuvir regimen | ABT-450 regimen1 |
| Headache | 32%-90% | 14%-26% |
| Fatigue | 10%-70% | 35%-47% |
| Insomnia | 10%-67% | 0%-26% |
| Nausea | 0%-44% | 21%-24% |
| Rash | 10%-60% | 6%-21% |
| Anemia | 0%-44% | No data |
| Dizziness | 4%-44% | 5%-29% |
| Myalgia | 0%-40% | No data |
| Diarrhea | 0%-30% | No data |
| Vomiting | No data | 0%-21% |
| Irritability | 0%-36% | No data |
| Pruritus | 0%-33% | 0%-21% |
| Decreased appetite | 0%-50% | No data |
| Upper respiratory tract infection | 0%-20% | No data |
| Arthralgia | 0%-30% | No data |
| Back pain | 0%-22% | No data |
| Pyrexia | 0%-18% | No data |
- Citation: Zeng QL, Zhang JY, Zhang Z, Wang LF, Wang FS. Sofosbuvir and ABT-450: Terminator of hepatitis C virus? World J Gastroenterol 2013; 19(21): 3199-3206
- URL: https://www.wjgnet.com/1007-9327/full/v19/i21/3199.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i21.3199